aTyr Pharma, Inc. (ATYR) — Financial statements
Income statement, balance sheet, and cash flow for aTyr Pharma, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.19↓19.1% | 0.24↓33.4% | 0.35↓96.6% | 10 | 0.00 | |
| Cost of Revenue | 2 | 0.00 | 0.00↓100.0% | 2↑30.0% | 1 | |
| Gross Profit | -1↓680.0% | 0.24↓33.4% | 0.35↓95.9% | 9↑766.5% | -1 | |
| Operating Expenses | ||||||
| R&D Expenses | 60↑10.8% | 54↑28.6% | 42↓1.2% | 43↑84.0% | 23 | |
| General & Administrative Expenses | 18↑27.7% | 14↑6.1% | 13↓7.2% | 14↑30.1% | 11 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00↑100.0% | -2 | 0.00 | |
| SG&A Expenses | 18↑27.7% | 14↑6.1% | 13↑5.6% | 12↑14.3% | 11 | |
| Other Expenses | -2 | 0.00 | 0.00 | 0.00↑100.0% | -1 | |
| Operating Expenses | 76↑11.9% | 68↑23.3% | 55↑0.3% | 55↑68.4% | 33 | |
| Total Costs & Expenses | 78↑14.2% | 68↑23.3% | 55↓2.7% | 57↑67.0% | 34 | |
| Operating Results | ||||||
| Operating Income | -78↓14.3% | -68↓23.7% | -55↓18.3% | -46↓36.4% | -34 | |
| Depreciation & Amortization | 2↑0.8% | 2↓43.8% | 3↑61.7% | 2↑30.0% | 1 | |
| EBITDA | -76↓14.6% | -66↓27.2% | -52↓16.7% | -45↓37.7% | -32 | |
| EBIT | -78↓14.3% | -68↓23.7% | -55↓18.3% | -46↓37.4% | -34 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00 | 0.00 | 0.00 | 0.00↑100.0% | -0.24 | |
| Other Income / Expenses | 4↓9.8% | 4↓13.9% | 5↑326.2% | 1↑345.8% | 0.24 | |
| Income Before Tax | -74↓15.8% | -64↓27.0% | -50↓11.1% | -45↓34.2% | -34 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -74↓15.8% | -64↓27.0% | -50↓11.1% | -45↓34.2% | -34 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -74↓15.8% | -64↓27.1% | -50↓11.1% | -45↓34.3% | -34 | |
| Bottom-Line Net Income | -74↓15.8% | -64↓27.1% | -50↓11.1% | -45↓34.3% | -34 | |
| EPS (Basic) | -0.80↑7.0% | -0.86↑8.5% | -0.94↑41.3% | -1.60↑9.6% | -1.77 | |
| EPS (Diluted) | -0.80↑7.0% | -0.86↑8.5% | -0.94↑41.3% | -1.60↑9.6% | -1.77 | |
| Weighted Average Shares | 93↑25.2% | 74↑38.5% | 54↑88.6% | 28↑48.9% | 19 | |
| Weighted Average Diluted Shares | 93↑25.2% | 74↑38.5% | 54↑88.6% | 28↑48.9% | 19 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.